The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Any lingering doubts over the feasibility of rolling out population-based cancer registries in low-income and middle-income countries ought to have been dispelled by the COVID-19 pandemic. Within ...
This little Jewish boy’s story shows there is hope for cystic fibrosis sufferers A breakthrough for some who suffer with the inherited condition that causes sticky mucus to build up in the lungs ...
Gov. Kathy Hochul laid out her policy agenda for 2025 during her State of the State address on Tuesday, Jan. 14, focusing on affordability, public safety, mental health, the environment, housing ...
NEW YORK CITY, NEW YORK / ACCESSWIRE / January 14, 2025 / Bionoid Pharma, Inc. (“Bionoid”) (OTC PINK:BINP) is pleased to provide a corporate update as it looks ahead to a promising year in 2025. The ...
In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback